AstraZeneca’s Farxiga broke ground last year with an FDA nod for heart failure patients with or without type 2 diabetes — a first-in-class approval. But Farxiga isn’t done innovating and is now looking at a approval in the coming months in another potential blockbuster indication.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,